Skip to main content
. 2013 May 7;108(10):1998–2004. doi: 10.1038/bjc.2013.227

Table 3. Treatment-related adverse events in ⩾2 patients.

  Tremelimumab+PF-3512676
 
6 mg kg−1+0.05 mg kg−1 (n=3)
10 mg kg−1+0.05 mg kg−1 (n=6)
15 mg kg−1+0.05 mg kg−1 (n=6)
10 mg kg−1+0.10 mg kg−1 (n=3)
10 mg kg−1+0.15 mg kg−1 (n=3)
  Total Grade⩾3 Total Grade⩾3 Total Grade ⩾3 Total Grade ⩾3 Total Grade ⩾3
Any adverse event
3
0
6
1
6
2
3
2
3
2
Injection-site reaction
3
0
6
0
6
0
3
0
3
0
Influenza-like illness
3
0
5
0
4
0
3
0
3
0
Diarrhoea
2
0
3
0
4
2
2
1
2
0
Nausea
1
0
3
0
3
1
1
0
1
0
Rash
1
0
3
0
2
0
2
1
0
0
Pruritus
1
0
1
0
4
0
1
1
0
0
Vomiting
1
0
3
0
2
1
0
0
0
0
Decreased appetite
1
0
2
0
1
0
1
0
0
0
Injection-site haematoma
1
0
1
0
2
0
0
0
0
0
Anaemia
0
0
2
0
1
0
0
0
0
0
Rash, generalised
0
0
0
0
1
0
0
0
2
0
Abdominal pain
0
0
1
0
0
0
0
0
1
0
Abdominal pain, upper
0
0
2
0
0
0
0
0
0
0
Colitis
0
0
0
0
0
0
1
1
1
1
Constipation
0
0
2
0
0
0
0
0
0
0
Dysgeusia
0
0
1
0
1
0
0
0
0
0
Fatigue 0 0 1 0 0 0 1 0 0 0